抗MDA5-DM合并快速进展性间质性肺病的预后预测因素研究进展

doi:10.20047/j.issn1673-7210.2023.16.10

Abstract
Figure/Table
References (31)
Related Citation (2)

Download: PDF (702 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis is a special subtype of dermatomyositis, which is very easy to be associated with rapidly progressive interstitial lung disease. In recent years, great progress has been made in the diagnosis and treatment of the disease through the joint efforts of doctors from respiratory department, rheumatology department, and severe medical department, but there are still high incidence rates and mortality rates in China. Comprehensive evaluation of predictive factors affecting patient prognosis is of great significance for timely adjustment of treatment plans and predicting outcomes. This article mainly summarizes the relevant domestic and foreign researches in recent years, and reviews research progress on the progress of predictive factors in anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis is combined with rapidly progressive interstitial lung disease.

Key words： Interstitial lung disease Anti-melanoma differentiation associated gene 5 antibody Dermatomyositis Predictive factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Nan LIU Hongju

Cite this article:

WANG Nan LIU Hongju. Research progress on prognostic predictive factors of anti-MDA5-DM combined with rapidly progressive interstitial lung disease[J]. 中国医药导报, 2023, 20(16): 50-53,79.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.16.10 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I16/50

[1] 孙宇新，张泽煜，邵池，等.抗黑色素瘤分化相关基因抗体相关性快速进展性间质性肺疾病的诊治进展[J].中华结核和呼吸杂志，2021，44（9）：837-839.
[2] Wu W，Guo L，Fu Y，et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis [J]. Clin Rev Allergy Immunol，2021，60（2）：293-304.
[3] Nombel A，Fabien N，Coutant F. Dermatomyositis with anti-MDA5 antibodies：bioclinical features，pathogenesis and emerging therapies [J]. Front Immunol，2021，12：773352.
[4] Yamaguchi K，Yamaguchi A，Onuki Y，et al. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age [J]. Mod Rheumatol，2021，31（1）：177-185.
[5] Wu Q，Wedderburn LR，McCann LJ. Juvenile dermatomyositis：latest advances [J]. Best Pract Res Clin Rheumatol，2017，31（4）：535-557.
[6] DeWane ME，Waldman R，Lu J. Dermatomyositis：clinical features and pathogenesis [J]. J Am Acad Dermatol，2020，82（2）：267-281.
[7] Gui X，Ma M，Ding J，et al. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis [J]. Rheumatology，2021，60（8）：3913-3922.
[8] Li Y，Li Y，Wu J，et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis [J]. J Immunol Res，2020，2020：2024869.
[9] 童奕，张昕，梁军.抗MDA5抗体相关皮肌炎合并急进性肺间质病变的临床特点[J].复旦学报（医学版），2021，48（1）：91-97.
[10] Wu W，Xu W，Sun W，et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis：a multi-centre cohort study [J]. Rheumatology，2022，61（1）：230-239.
[11] Liang J，Cao H，Ke Y，et al. Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies：a retrospective case-control study [J]. Front Med，2020，7：12.
[12] Sontheimer RD. MDA5autoantibody-another indicator of clinical diversity in dermatomyositis [J]. Ann Transl Med，2017，5（7）：160.
[13] Chino H，Sekine A，Baba T，et al. Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody：rapidly progressive perilobular opacity [J]. Intern Med， 2019，58（18）：2605-2613.
[14] Wang C，Du J，Mei X，et al. The value of effective lung ven- tilation area ratio based on CT image analysis is a new index to predict the shorter outcome of anti-melanoma differentiation-associated protein 5 positive dermatomyositis associated interstitial lung disease：a single-center retrospective study [J]. Front Med，2021，8：728487.
[15] Cao H，Liang J，Xu D，et al. Radiological characteristics of patients with anti-MDA5-antibody-positive dermatomyositis in 18F-FDG PET/CT：a pilot study [J]. Front Med，2021， 8：779272.
[16] Sakamoto S，Okamoto M，Kaieda S，et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis [J]. Respir Investig，2018，56（6）：464-472.
[17] 徐婷，张光峰，林浩博，等.抗黑色素瘤分化相关基因5抗体阳性皮肌炎合并快速进展性间质性肺病的临床及预后分析[J].中华风湿病学杂志，2021，25（6）：361-367.
[18] Ye Y，Fu Q，Wang R，et al. Serum KL-6 level is a prognostic marker in patients with anti-mda5 antibody-positive dermatomyositis associated with interstitial lung disease [J]. J Clin Lab Anal，2019，33（8）：e22978.
[19] Gono T，Kawaguchi Y，Satoh T，et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis [J]. Rheumatology（Oxford），2010，49（9）：1713-1719.
[20] Motegi SI，Sekiguchi A，Toki S，et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease [J]. Eur J Dermatol，2019，29（5）：511-517.
[21] Zhu D，Qiao J，Tang S，et al. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis [J]. Rheumatology，2021，60（8）：3896-3903.
[22] So J，So H，Wong VT，et al. Predictors of rapidly progressive-interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis [J]. Rheumatology（Oxford），2022， 61（11）：4437-4444.
[23] Liu T，Li W，Zhang Z，et al. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis [J]. BMC Pulm Med，2022，22（1）：316-323.
[24] Shen YW，Zhang YM，Huang ZG，et al. Increased levels of soluble CD206 associated with rapidly progressive interstitial lung disease in patients with dermatomyositis [J]. Mediators Inflamm，2020，2020：7948095.
[25] Horiike Y，Suzuki Y，Fujisawa T，et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-mda5 antibody positive dermatomyositis associated ILD [J]. Rheumatology，2019，58（12）：2143-2152.
[26] Fujisawa T，Hozumi H，Yasui H，et al. Clinical significance of serum chitotriosidase level in anti-mda5 antibody-positive dermatomyositis-associated interstitial lung disease [J]. J Rheumatol，2019，46（8）：935-942.
[27] Jiang L，Wang Y，Peng Q，et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody [J]. Clin Rheumatol，2019，38（6）：1655-1663.
[28] Yasuda H，Ikeda T，Hamaguchi Y，et al. Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia：the relation between the disease activity and the serum interleukin-6 level [J]. J Dermatol，2017，44（10）：1164-1167.
[29] Shimizu T，Koga T，Furukawa K，et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis [J]. J Intern Med，2021，289（2）：206-220.
[30] Huang W，Chen D，Wang Z，et al. Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease [J]. Rheumatology（Oxford），2023，62（3）：1197-1203.
[31] Lian X，Zou J，Guo Q，et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease：the FLAIR model [J]. Chest，2020，158（4）：1535- 1545.